Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Location: United States, California, Foster City
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 07.08.2021 | New Enterp... | nea.com |
| - | Biobrit | biobrit.co... |
Mentions in press and media 16
| Date | Title | Description |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 10.01.2022 | Geron : January 2022 Corporate Presentation | CORPORATE PRESENTATION January 2022 Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the "safe harbor" provisions of the Priv... |
| 14.09.2021 | Geron : R.W. Baird Global Healthcare Conference | R.W. Baird Global Healthcare Conference John A. Scarlett, MD Chairman & CEO September 14, 2021 Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made... |
| 13.09.2021 | Geron : HC Wainwright Healthcare Conference | HC Wainwright Healthcare Conference John A. Scarlett, MD Chairman & CEO September 13, 2021 Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pur... |
| 26.01.2021 | Arriello Announces Signing of First US Company to Use IntelliCASE for Clinical Pharmacovigilance Reporting | The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. DUBLIN (PRWEB) January 26, 2021 Arriello, a global expert in pharmacovigilance consulting and life science outs... |
| 12.10.2010 | First patient receives embryonic stem cells in spinal injury trial | Physicians injected the first-ever patient with millions of stem cells derived from human embryos in a clinical trial aimed at proving the treatment is safe for people with spinal cord injuries. The trial, sponsored by Geron Corp. (NSDQ:GER... |
| 07.10.2010 | Nurse practioner: Let’s do what we’re trained to do (Morning Read) | Still a long way to go. Two mice — one dragging its hind leg and incontinent; the other, with better use of its hind legs — showed the promise of stem cells for treating spinal cord injury at the World Stem Cell Summit in Detroit, Michigan,... |
| 16.12.2009 | Advanced Cell Technology Betting Future on Embryonic Stem Cell Therapy for Eye Disease | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Advanced Cell Technology is banking on an experimental cellular therapy for a rare eye disease to show the world that controversial embryonic stem cells have a place in treati... |
| 10.08.2007 | Life sciences briefing: Friday, Aug. 10, 2007 | (CORRECTED: See below.) Featured companies: VistaGen Therapeutics, MindWeavers, Cutanea Life Sciences, Heptares Therapeutics VistaGen raises $3.75M for stem-cell based drug discovery — South San Francisco, Calif.-based VistaGen Therapeutics... |
| 10.05.2007 | Roundup: Anemia drugs under assault, stem-cell trial moves forward, medical interventions and poor “quality of death,” and more | Is the bell tolling for EPO? — The news keeps going from bad to worse for the wonder drugs of biotech — the anemia treatments known as ESAs or EPO, shorthand for “erythropoiesis stimulating agents” and “erythropoietin,” respectively. Earlie... |
Show more